Page 4 - Nasdaq Stro News Today

Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price target lowered by analysts at JMP Securities from $20.00 to $17.00 in a research note issued to investors on Monday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. JMP Securities’ target price would indicate a potential upside of 294.43% from the […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price target trimmed by HC Wainwright from $20.00 to $16.00 in a research note published on Friday, The Fly reports. The firm currently has a buy rating on the stock. Other equities research analysts have also issued research reports about the company. Truist Financial boosted their price […]

Wedbush reissued their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO – Get Rating) in a research report sent to investors on Friday, Benzinga reports. Wedbush currently has a $20.00 price target on the stock. A number of other equities analysts have also recently commented on STRO. Piper Sandler raised their target price on Sutro […]

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,580,000 shares, a decline of 16.0% from the February 28th total of 1,880,000 shares. Based on an average daily volume of 535,700 shares, the short-interest ratio is […]

- STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at...

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do...

Sutro Biopharma (NASDAQ:STRO – Get Rating) and Talaris Therapeutics (NASDAQ:TALS – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings & Valuation This table compares Sutro Biopharma and […]

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) have been assigned an average recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price objective cut by analysts at HC Wainwright from $35.00 to $30.00 in a note issued to investors on Wednesday, The Fly reports. HC Wainwright’s target price points to a potential upside of 462.85% from the company’s current price. Several other research firms have also recently weighed […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) issued its quarterly earnings data on Monday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.08), MarketWatch Earnings reports. Sutro Biopharma had a negative net margin of 170.55% and a negative return on equity of 32.96%. STRO traded up […]